Many ketamine clinics in the United States offer treatments for various behavioral health conditions, including depression. However, many healthcare providers who work for these clinics are not trained in psychiatry and/or counseling. There are various legal issues with this type of fact pattern. Among other things, are healthcare providers who are not trained in psychiatry
Ketamine telehealth has been a wild ride these last few years. Every few months I give an update, and every time I do, things seem to change dramatically. For example, in just a few short weeks in February 2023, the situation went from “bad” to “good” (at least sort of) as it became clear that
Anyone familiar with the cannabis industry knows how difficult it is to make money. Things are going to be even worse for people in the state-legal psychedelics industry – much worse. There are a few key reasons for this. I should note that this post is focused on the state-legal psychedelics industry (i.e., service centers)
A few weeks ago, we held a webinar about ketamine regulation and the future of psychedelic medicine (for a recording, click here). At the time, there were big changes on the horizon for ketamine telehealth. In the last few weeks, there have been a few pretty significant developments that merit some attention. For some background,
Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Last week, we presented a psychedelics webinar entitled “How to Protect Your Psychedelics Business.” The panelists were Paul Coble from our Phoenix office), me (Griffen Thorne from our Los Angeles office), and Graham Pechenik of Calyx Law in San Francisco. In the webinar, we presented on business law and intellectual property issues that will affect
On September 6, 2022, the San Francisco Board of Supervisors unanimously voted to pass a resolution aimed at decriminalizing psychedelics. This is yet another victory in the battle against prohibition. But it’s important to remember that decriminalization is very different from legalization– just see my older summary of a host of decriminalization efforts. Decriminalization does
In 2023, Oregon will have a regulated psilocybin market. Colorado voters will have a chance to vote on something similar this fall (although Initiative 58 would not take effect until 2024). Other than that, not a single other state has any form of psychedelic regulation in the works. Last week, an attempt to simply decriminalize
In 2021, California State Senator Scott Wiener introduced SB-519, a statewide psychedelics decriminalization bill. Senator Wiener didn’t have the support to push the bill all the way forward in 2021, so he gathered momentum for a 2022 vote. After a gutting by the California Assembly, the state won’t decriminalize psychedelics in 2022. I’ve regularly blogged on
A statewide psychedelics decriminalization bill that’s been on pause for almost a year was recently set for a legislative hearing next month. This is huge news for California psychedelics advocates, even if we don’t have a ton of information on what is likely to happen just yet. In 2021, California State Senator Scott Wiener introduced
